Governance
Call for Applications for KHI’s Board of Directors
The Kidney Health Initiative (KHI) Nominating Committee invites nominations for members to join KHI’s Board of Directors (BOD). Upon appointment, all BOD members serve through one of the following committees: Biologics, Devices, Drug, or Strategy.
The Nominating Committee seeks candidates who enhance the balance of the Board and reflect the KHI membership. KHI priorities for 2027 include but are not limited to acute kidney injury, genetic therapies, kidney transplant, patient engagement, pediatrics, rare kidney diseases, and vascular access. The committee will consider applications from candidates with the profiles described below. Vacancies are determined by current member term limits and other governance considerations.
- Patients or patient advocates interested in kidney diseases and related conditions.
- Representatives from small, mid, or large private sector companies aligned with KHI’s mission.
- Health care professionals with expertise in kidney diseases (ASN membership required).
- Members at-large with varied expertise in kidney biologic, device and drug development.
Selected candidates will serve a three-year term from January 1, 2027, through December 31, 2029.
Call for Applications for KHI’s Patient and Family Partnership Council
The Kidney Health Initiative (KHI) is currently accepting applications for its Patient and Family Partnership Council (PFPC). Selected individuals will serve a three-year term beginning January 1, 2027, with the possibility of renewal for one additional term.
The PFPC is charged with driving patient-centered innovation in every stage of the development of biologics, devices, and drugs by:
- Assisting with the development of strategic priorities and goals to help federal liaisons, KHI members and patients drive patient-centered innovation.
- Providing patients and care partners an equal and fair representation in product development conversations by developing and leveraging educational and training tools.
- Contributing to and leading patient-centered projects and initiatives.
- Advising on project proposals and recommending patient and care partner representation for KHI workgroups and projects.
KHI’s governance framework ensures transparency, accountability, and collaborative decision-making across all initiatives. Our leadership includes voices from industry, patient advocacy, research, and government—working together to guide our mission.
- The KHI Board of Directors is charged with executing the consortium’s mission and objectives. It includes the Strategy, Biologics, Devices, and Drugs Committees.
- KHI’s governance and oversight structure was updated in 2022, revising the charge and governance of its committees and frameworks for defining strategy and approving activities. For more details, read the KHI Board of Directors Governance Task Force Executive Summary.
- The KHI PFPC advises and makes recommendations on projects and other activities to ensure that the voice, experiences, and involvement of people with kidney diseases are included in the development of kidney drugs, devices, and biologics.